Patents Assigned to Merck
  • SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS
    Publication number: 20180162874
    Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: June 20, 2016
    Publication date: June 14, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gregori J. Morriello, Michael P. Dwyer, Lehua Chang, Yili Chen, Ming Wang, Ashley Forster, Richard Berger, Kausik k Nanda, Jaime L Bunda, William D Shipe
  • COMBINATION OF AN ANTI-IL-10 ANTIBODY AND A CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
    Publication number: 20180161427
    Abstract: The present disclosure describes combination therapies comprising an anti-IL-10 antibody or antigen-binding fragment thereof and a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 26, 2016
    Publication date: June 14, 2018
    Applicants: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying YU, Elliot Keith CHARTASH, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20180163136
    Abstract: The invention relates to compounds of the formula I, and to a liquid-crystalline medium, preferably having a nematic phase and negative dielectric anisotropy, which comprises a) one or more compounds of the formula I and b) one or more compounds of the formula II in which the parameters have the respective meanings indicated in Claim 1, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PALC, FFS or IPS effect,
    Type: Application
    Filed: May 12, 2016
    Publication date: June 14, 2018
    Applicant: Merck Patent GmbH
    Inventors: Martin ENGEL, Thorsten KODEK, Ingo ALMEROTH, Rocco FORTTE, Oliver HEPPERT
  • DEEP EUTECTIC SOLVENTS AND/OR IONIC LIQUIDS IN CELL CULTURE MEDIA
    Publication number: 20180163171
    Abstract: The present invention relates to cell culture media compositions comprising deep eutectic solvents and/or ionic liquids.
    Type: Application
    Filed: May 2, 2016
    Publication date: June 14, 2018
    Applicant: Merck Patent GmbH
    Inventors: Jochen Bastian SIECK, Michael Howard RAYNER, Joerg VON HAGEN, Claudia KNACK
  • POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS
    Publication number: 20180163137
    Abstract: Polymerisable compounds, processes and intermediates for the preparation thereof, liquid-crystal (LC) media comprising them, and the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
    Type: Application
    Filed: December 7, 2017
    Publication date: June 14, 2018
    Applicant: Merck Patent GmbH
    Inventors: Dmitry Ushakov, Kaja Christina Deing
  • LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY
    Publication number: 20180163134
    Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising one or more compounds of the formula I and/or TINUVIN 770®, in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays, especially active-matrix displays and in particular TN, IPS and FFS displays, containing these media.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 14, 2018
    Applicant: Merck Patent GmbH
    Inventors: Achim GOETZ, Hee-Kyu LEE, Mark GOEBEL
  • Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof
    Patent number: 9994518
    Abstract: Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “RIa”, “RIb”, “RIc”, “RId”, “RIe”, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 12, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Kenneth Leavitt, Brendan Crowley, Ian M. Bell, Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen, Patrick Bazzini, Aurelie Fromeyer
  • Process for producing cell culture media
    Patent number: 9994810
    Abstract: The present invention relates to an a process for manufacturing dry powder cell culture media. The preparation and usage of mixed particles generated by co-lyophilisation leads to homogenously blended cell culture media.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: June 12, 2018
    Assignee: MERCK PATENT GMBH
    Inventor: Joerg Von Hagen
  • Method for the preparation of fibers from a catalyst solution, and articles comprising such fibers
    Patent number: 9994972
    Abstract: The present invention relates to a method for the preparation of fibers from a catalyst solution by electrospinning and further to articles comprising such fibers.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: June 12, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Onur Kas, Gabriel Tkacik, Ashley Moore, Ryan Sylvia
  • Hole transport material
    Patent number: 9997714
    Abstract: The invention relates to 2,2?,7,7?-tetrakis-(N,N?-di-4-methoxy-3-methylphenylamine)-9,9?-spirofluorene, to a process for its preparation, and to its use as hole transport material for electronic or optoelectronic devices, especially for solid-state dye-sensitized solar cells.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: June 12, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Hiromi Shinohara, Atsushi Sawada, Elvira Montenegro, Heinrich Becker
  • Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
    Patent number: 9994577
    Abstract: The present invention provides compounds of Formula (i). Furthermore, pharmaceutical compositions are provided comprising at least one compound of Formula (i), for the treatment of parasitic diseases including malaria, as well as neurodegenerative diseases.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: June 12, 2018
    Assignee: MERCK PATENT GMBH
    Inventor: Thomas Spangenberg
  • HIV protease inhibitors
    Patent number: 9994587
    Abstract: The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z1, Z2, V1, V2, V3, R6, R6A, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: June 12, 2018
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: John A. McCauley, David Jonathan Bennett, Christopher J. Bungard, Thomas J. Greshock, M. Katharine Holloway, Peter D. Williams, Christian Beaulieu, Sheldon Crane, Stephanie Lessard, Daniel Mckay, Carmela Molinaro, Oscar Miguel Moradei, Vijayasaradhi Sivalenka, Vouy Linh Truong, Satyanarayana Tummanapalli
  • Bridged diazepane orexin receptor antagonists
    Patent number: 9994570
    Abstract: The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: June 12, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Thomas S. Reger, Anthony J. Roecker
  • Anti-pembrolizumab antibodies
    Patent number: 9995753
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to the antibody pembrolizumab (pembrolizumab). These antibodies are useful, for example, for use as positive controls in assays for detecting the presence of anti-drug antibodies in a sample, e.g., the blood of a patient who has been administered pembrolizumab.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: June 12, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: LiNa Loo, Shuangping Shi
  • OPTICAL SWITCHING LAYER FOR USE IN AN OPTICAL SWITCHING ELEMENT
    Publication number: 20180157088
    Abstract: The present invention presents a switching layer S for use in a switching element which has forwards-scattering properties in at least one switching state. Furthermore, a switching element which comprises the switching layer S and a window element which includes the switching element are presented.
    Type: Application
    Filed: April 1, 2016
    Publication date: June 7, 2018
    Applicant: Merck Patent GmbH
    Inventors: Michael JUNGE, Andreas BEYER, Ties DE JONG
  • PHOSPHORS AND PHOSPHOR-CONVERTED LEDS
    Publication number: 20180155621
    Abstract: The present invention relates to pyrosilicate phosphors, to a process for the preparation thereof and to the use thereof as conversion phosphors. The present invention also relates to an emission-converting material comprising the conversion phosphor according to the invention, and to the use thereof in light sources, in particular pc-LEDs (phosphor converted light emitting devices). The present invention furthermore relates to light sources, in particular pc-LEDs, and to lighting units which comprise a primary light source and the emission-converting material according to the invention.
    Type: Application
    Filed: March 30, 2016
    Publication date: June 7, 2018
    Applicant: Merck Patent GmbH
    Inventors: Aleksander ZYCH, Ralf PETRY, Mathias RAPPHAHN, Ingo KOEHLER, Stefan TEWS
  • LIQUID-CRYSTALLINE MEDIUM AND HIGH-FREQUENCY COMPONENTS COMPRISING SAME
    Publication number: 20180155625
    Abstract: The present invention relates to liquid-crystalline media comprising one or more chiral compounds and one or more compounds selected from the group of compounds of formulae I, II and III, in which the parameters have the meaning indicated in claim 1, and to components comprising these media for high-frequency technology, in particular phase shifters and microwave array antennas.
    Type: Application
    Filed: May 19, 2016
    Publication date: June 7, 2018
    Applicant: Merck Patent GmbH
    Inventors: Michael WITTEK, Dagmar KLASS
  • TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20180155365
    Abstract: The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I). and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R1, R2, R3 and R7 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: November 30, 2017
    Publication date: June 7, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Thomas H. Graham, Tao Yu, Yonglian Zhang, John A. McCauley
  • SUSTAINED RELEASE FORMULATION AND TABLETS PREPARED THEREFROM
    Publication number: 20180154000
    Abstract: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.
    Type: Application
    Filed: June 21, 2016
    Publication date: June 7, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pranav Gupta, David Monteith
  • METHOD FOR THE PRODUCTION OF PRAZIQUANTEL
    Publication number: 20180155339
    Abstract: The present invention relates to a method for the racemization of enantiomerically pure or enantiomerically enriched Praziquantel under basic conditions and a method for the production of (R)-Praziquantel in enantiopure or enantiomerically enriched form, which comprises the racemization method.
    Type: Application
    Filed: November 17, 2015
    Publication date: June 7, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Andreas WAECHTLER, Hadia SALEH-KASSIM, Christian JASPER, Joern KOLB, David MAILLARD